Daunorubicin. Results in childhood leukaemia.
D000293:Adolescent; D000380:Agranulocytosis / Q000139:chemically induced; D000740:Anemia / Q000139:chemically induced; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D009504:Neutrophils; D011239:Prednisolone / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000627:therapeutic use
D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D003630:Daunorubicin